Pulse Biosciences announced today that the FDA granted investigational device exemption (IDE) for a pulsed field ablation (PFA) study.

Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond ...

The Company’s nsPFA™ System demonstrates the ability to provide cardiac ablation and mapping capabilities with a single catheter in preclinical studies The Company collaborated with CardioNXT to ...

Nanosecond PFA 360° Cardiac Catheter for AF ablation to be highlighted in late-breaking clinical science session and in a live case transmission “Since joining the Company’s Board last year I have ...

Pulse Biosciences (PLSE) just cleared a key regulatory hurdle, with the FDA signing off on its Investigational Device Exemption for the nPulse Cardiac Catheter Ablation System in atrial fibrillation, ...

Shorter, nanosecond pulses for treating atrial fibrillation differentiate the company’s approach from existing pulsed field ...

Nanosecond PFA 360° Cardiac Catheter for AF ablation to be highlighted in presentations and in a live case transmission “We are gaining significant momentum generating clinical and preclinical ...

Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company progressing Nano-Pulse Stimulation™ (NPS™) technology, today announced U.S. Food and Drug Administration (FDA) clearance of ...

MIAMI--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced it will report ...

Management reiterated expectations to generate initial revenue from the percutaneous electrode in the second half of the year, noting, “This initial revenue recognition will value based on the ...

HAYWARD, Calif.--(BUSINESS WIRE)-- Pulse Biosciences, Inc. (Nasdaq: PLSE), a company with a primary focus on leveraging its novel and proprietary CellFX Nanosecond Pulsed Field Ablation (nsPFA) ...

An announcement from Pulse Biosciences ( ($PLSE) ) is now available. On December 9, 2025, Pulse Biosciences announced a research collaboration ...